Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Assis, Tália Santana Machado de; Rabello, Ana; Cota, Gláucia; Werneck, Guilherme Loureiro; Azeredo-da-Silva, André Luís Ferreira de.
Affiliation
  • Assis, Tália Santana Machado de; Centro Federal de Educação Tecnológica de Minas Gerais. Contagem. BR
  • Rabello, Ana; Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Grupo de Pesquisa. Belo Horizonte. BR
  • Cota, Gláucia; Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Grupo de Pesquisa. Belo Horizonte. BR
  • Werneck, Guilherme Loureiro; Universidade do Estado do Rio de Janeiro. Instituto de Medicina Social. Departamento de Epidemiologia. BR
  • Azeredo-da-Silva, André Luís Ferreira de; Instituto de Avaliação de Tecnologia em Saúde. Porto Alegre. BR
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;52: e20180272, 2019. tab, graf
Article in En | LILACS | ID: biblio-1041550
Responsible library: BR1.1
ABSTRACT
Abstract

INTRODUCTION:

Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.

METHODS:

A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.

RESULTS:

IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.

CONCLUSIONS:

These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Amphotericin B / Cost-Benefit Analysis / Leishmaniasis, Visceral / Meglumine / Antiprotozoal Agents Type of study: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do sul / Brasil Language: En Journal: Rev. Soc. Bras. Med. Trop Journal subject: MEDICINA TROPICAL Year: 2019 Document type: Article Affiliation country: Brazil Country of publication: Brazil
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Amphotericin B / Cost-Benefit Analysis / Leishmaniasis, Visceral / Meglumine / Antiprotozoal Agents Type of study: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do sul / Brasil Language: En Journal: Rev. Soc. Bras. Med. Trop Journal subject: MEDICINA TROPICAL Year: 2019 Document type: Article Affiliation country: Brazil Country of publication: Brazil